ASH 41020
Alternative Names: ASH-41020; Dendranib; H74DS3M8Latest Information Update: 13 Jun 2024
At a glance
- Originator Ashvattha Therapeutics
- Class Anti-inflammatories; Neuroprotectants
- Mechanism of Action Colony-stimulating factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple sclerosis
Most Recent Events
- 10 Jun 2024 Pharmacodynamics data from a preclinical study in Multiple sclerosis released by Ashvattha Therapeutics
- 22 Aug 2023 Preclinical trials in Multiple sclerosis in USA (unspecified route) (Prior to August,
- 22 Aug 2023 Pharmacodynamics data from a preclinical study in Multiple sclerosis released by Ashvattha Therapeutics